Getting press coverage now10 May 2023 12:53
(Alliance News) - SkinBioTherapeutics PLC on Wednesday said that a partner has plans to undertake additional studies on SkinBiotix, which could enhance its commercial potential.
SkinBioTherapeutics is a Newcastle Upon Tyne, England-based life science company focused on skin health. Its partner Sederma is a division of Croda International PLC, a Yorkshire, England-based speciality chemicals company.
SkinBioTherapeutics first signed a commercial agreement with Croda in November 2019, under the terms of which Sederma was made responsible for the development, manufacturing and commercialisation of SkinBiotix technology.
The further studies are expected to take an additional three to four months, and would run from November 2023 through to the first quarter of 2024.
Any licensed products resulting from the agreement with SkinBioTherapeutics will be sold to Croda's global portfolio of Personal Care division customers.